Our EndoSign® cell collection device has received 510(k) clearance from the FDA, enabling earlier and more efficient detection of esophageal pre-cancer and other conditions. #DetectToProtect #FDA

Clinicians are being urged to reduce low yield endoscopies, and earlier risk stratification could be key to this. EndoSign® capsule sponge testing offers minimally invasive triage to support targeted referral. Learn more: endosign.com #Endoscopy #BarrettsOesophagus

What is the difference between capsule endoscopy and capsule sponge technology? Explore more of our frequently asked questions: #UpperGI #Diagnostics #OesophagealCancer #Reflux #Endoscopy

31-MarYou may know EndoSign® as the ‘pill on a string’ – but what is it? A minimally invasive triage tool that collects oesophageal cells to assess #reflux and Barrett’s risk. Learn more: endosign.com #OesophagealCancer #Reflux

Oesophageal cancer is often diagnosed late, impacting outcomes. 5 year survival can be ~95 % when detected early, but reduces to 5-40 % at advanced stages. EndoSign® enables minimally invasive risk stratification for targeted referrals. Learn more: endosign.com

Up to 75 % of UK #gastroscopies may be performed in patients with <1 % cancer risk. Earlier risk stratification could reduce low yield procedures. EndoSign® supports minimally invasive assessment to better target #endoscopy. Learn more: endosign.com

What do patients think of EndoSign® capsule sponge test? Read more about the patient experience here: #HeartburnHealthCheck #OesophagealCancer #EarlyDiagnosis #NHSInnovation

💭 What does long-term follow-up 📊 on low-risk patients w/ Barrett's esophagus triaged with 🧽 capsule sponge look like❓ ✅ Check out these interesting and reassuring results from a study (relatively small sample size) @FrontGastro_BMJ 🖇️ bit.ly/4moRYQ1 that showed ↪️ No significant differences in the detection of dysplasia or cancer in patients with follow-up endoscopy vs repeat capsule sponge testing and endoscopy ↪️ All cases w/ HGD and cancer were detected by repeat capsule sponge testing w/ positive biomarkers (atypia and p53) 👏 Thank you to authors @siobhan_chien @GastronautIan Paul Glen Gavin Bryce Michael Miller Neil Cruickshank Andrew Crumley Jonathan Fletcher Ivan Gunjaca Perminder Phull @JKApollos Kevin Robertson Grant M Fullarton @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @ulstergastro #GITwitter

1 in 100 people in the UK may require surveillance for Barrett’s oesophagus, creating sustained #endoscopy demand. EndoSign® provides minimally invasive risk stratification, helping prioritise those most likely to benefit from endoscopy. Learn more: endosign.com

Endoscopy demand in the NHS is rising. Capacity is finite. Non-endoscopic diagnostics such as EndoSign® can support risk stratification, helping ensure endoscopy is reserved for patients who need it most. endosign.com/hcp/overview #CancerInnovation #EarlyDetection

The National Cancer Plan for England includes piloting capsule sponge heartburn health checks in pharmacies. Earlier, minimally invasive assessment may reduce unnecessary endoscopy referrals. Discover EndoSign®: assets.publishing.service.go… #NationalCancerPlan #EarlyDiagnosis

🧪 Capsule Sponge Triage in Reflux — Can We Reduce Unnecessary Endoscopy? 4-year prospective cohort, 871 patients. Key findings: • 88% adequate samples • 62% avoided endoscopy • Abnormal CS (~10%) strongly predicted significant pathology • PPV for Barrett’s: 43.5% • NPV: 98.2% • >97% patient acceptability Detected: 1 cancer, 2 dysplasia, 34 Barrett’s cases. Long-term follow-up confirmed safety. Takeaway: Capsule sponge safely stratifies reflux patients, increases diagnostic yield, and optimizes endoscopy resources. #GERD #BarrettsEsophagus #Endoscopy #GIInnovation #GastroAGI

How do we detect Barrett’s oesophagus earlier without overwhelming endoscopy? EndoSign® capsule sponge testing enables early risk stratification, supporting more efficient use of NHS endoscopy capacity. Discover more: endosign.com/hcp/overview #BarrettsOesophagus #NHS

Expanding NHS FIT screening is a major step for early bowel cancer detection. But rising referrals mean #endoscopy capacity must be protected. Triage tools such as EndoSign® for oesophageal risk could help free capacity for bowel cancer patients. endosign.com/hcp/overview

For Oesophageal Cancer Awareness Month, we are sharing Eddie’s story - a powerful reminder of why early detection matters. After decades of heartburn, and no new symptoms, the EndoSign® test helped catch his cancer early. Watch here: youtu.be/4ICuevA92rQ

Great to see the National Cancer Plan backing proven diagnostics like the EndoSign® capsule sponge test. It’s already used across the NHS—now national policy can help end postcode variation and ensure more patients benefit from #earlierdiagnosis. gov.uk/government/news/gover…

We've done it again! Cyted Health has been shortlisted for the @HSJnews Independent Healthcare Providers Awards 2026, this time in the Best Provider of Community and Primary Care category for the #CYTOPRIME2 project. Thank you to all involved! lnkd.in/eEPUhNik

🚨 🗣️ Fantastic new original research from the CYTOPRIME 2 study 💥. Thanks to @DrDanielleMorr1 @CytedHealth and team for demonstrating that capsule sponge testing 🧽 is a practical and scalable approach to earlier detection of Barrett's oesophagus and oesophageal cancer 👏 . Should we be implementing this in the community as a screening test for patients with GORD 🤔 💭 ?! fg.bmj.com/content/early/202… @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media #GITwitter #gastroenterology #Endoscopy #MedEd

We’re proud to have been shortlisted alongside @NHSScotlandRBLX for the @HSJnews Independent Healthcare Provider of the Year Award 2025! This second nomination is a real testament to our work enhancing early cancer detection across the UK.

Delighted to be featured on @TheLancet podcast sharing our findings from our recent BE surveillance paper published in the Lancet! Tune in wherever you get your podcasts: thelancet.com/multimedia/pod… #podcast #surveillance #barretts

New in The Lancet: a major step forward in Barrett’s esophagus surveillance. Our real-world study shows how a capsule sponge test biomarker analysis can stratify risk - helping to prioritise care & streamline endoscopy pressures. thelancet.com/journals/lance…